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Background: It is well established that genetic and epigenetic alterations are common events in prostate cancer,
which may lead to aberrant expression of critical genes. The importance of epigenetic mechanisms in prostate
cancer carcinogenesis is increasingly evident. In this study, the focus will be on histone modifications and the
primary objectives are to map H3K27me3 marks and quantify RAR beta 2, ER alpha, SRC3, RGMA, PGR, and EZH2
gene expressions in prostate cancer tissues compared to normal tissues. In addition, a data analysis was made in
connection with the clinicopathological parameters.
Methods: 71 normal specimens and 66 cancer prostate tissues were randomly selected in order to assess the
proportion of the repressive H3K27me3 mark and gene expression. H3K27me3 level was evaluated by ChIP-qPCR
and mRNA expression using RT-qPCR between prostate cancer and normal tissues. Subsequently, western-blotting
was performed for protein detection. The analysis of variance (ANOVA) was performed, and Tukey’s test was used
to correct for multiple comparisons (p-value threshold of 0.05). The principal component analysis (PCA) and
discriminant factorial analysis (DFA) were used to explore the association between H3K27me3 level and
clinicopathological parameters.
Results: The study demonstrated that H3K27me3 level was significantly enriched at the RAR beta 2, ER alpha, PGR,
and RGMA promoter regions in prostate cancer tissues compared to normal tissues. After stratification by
clinicopathological parameters, the H3K27me3 level was positively correlated with Gleason score, PSA levels and
clinical stages for RAR beta 2, ER alpha, PGR, and RGMA. High H3K27me3 mark was significantly associated with
decreased RAR beta 2, ER alpha, PGR and RGMA gene expressions in prostate cancer sample compared to the
normal one. Moreover, the results showed that mRNA level of EZH2, AR and SRC3 are upregulated in prostate
cancer compared to normal prostate tissues and this correlates positively with Gleason score, PSA levels and
clinical stages. Obviously, these observations were confirmed by protein level using western-blot.
Conclusions: This data clearly demonstrated that H3K27me3 level correlated with aggressive tumor features. Also
this study revealed that reverse correlation of RAR beta 2, ER alpha, PGR, and RGMA expressions with EZH2, SRC3,
and AR expressions in prostate cancer tissues suggests that these genes are the target of EZH2. Therefore, all
therapeutic strategies leading to histone demethylation with epigenetic drugs such as histone methyltransferase
inhibitor may be relevant treatments against prostate cancer.
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Prostate cancer is the most frequently diagnosed cancer
in men in the western world and second leading cause
of cancer death in males worldwide [1]. In 2011, prostate
cancer represented 71,200 new cases and 8,700 deaths in
France. Prostate cancer like many other malignancies
arises from progressive genetic and epigenetic alterations
[2]. Tumorigenesis and progression of prostate cancer
result from the accumulation of genetic and epigenetic
alterations. Epigenetic modifications include several differ-
ent phenomena, such as DNA methylation [3], histone
modifications [4], and microRNAs (miR) regulation [5].
Basically, epigenetics regulate gene expression and play an
important role in carcinogenesis [6].
In this study, the focus is put on histone modifications
and their role in prostate cancer progression. Studies have
shown that histone modifications contribute to the onset
and progression of prostate cancer [7]. Common histone
modifications leading to gene silencing in prostate cancer
include histone H3 lysine 9 methylation (H3K9me3), his-
tone deacetylation, and polycomb-based histone H3 lysine
27 trimethylation (H3K27me3) [8]. Polycomb-mediated
H3K27me3 has been shown to play critical role in diverse
biological processes, such as development, stem cell main-
tenance, transcriptional silencing of homeotic gene, and in
early steps of X-chromosome inactivation in women [9].
So far, it is important to understand the role of histone
modifications in the control of gene transcription. H3K
27me3 is catalyzed by the polycomb enhancer of zeste
homolog 2 (EZH2), the catalytic core protein of the poly-
comb repressor complex 2 (PRC2). This histone methyl-
transferase is well known in initiating target gene silencing
by promoting H3K27me3 leading to the chromatin
condensation [10]. Many authors have demonstrated that
overexpression of EZH2 was strongly associated with
progression and invasion of prostate cancer [11]. In
addition, some studies showed that EZH2 is upregulated
by aberrant expression of MYC transcription factor and
microRNA [12]. Clearly, MYC promotes EZH2 expression
by repressing the expression of miR-26a and miR-26b,
which might be a negative regulator of EZH2 [13].
Kondo et al. (2008) found that up to 5% of promoters
were enriched with H3K27me3 and showed none or low
DNA methylation in their promoters. This data establish
EZH2-mediated H3K27me3 like a mechanism of gene
silencing in cancer potentially independent of DNA
methylation [8].
In fact, to study histone methylation, a selection of six
genes involved in prostate cancer was made, including
RAR beta 2, ER alpha, PGR, RGMA, EZH2, and SRC3.
The retinoic acid receptor (RAR) is a transcription
factor that regulates transcription of set genes involved
in biological processes such as apoptosis, proliferation
and cellular differentiation. Of course, RAR beta 2 is oneof the genes involved in aberrant methylation in human
prostate cancer [14,15]. Previous studies reported that the
methylated promoter region of RAR beta 2 in prostate
cancer cell lines (LNCaP and PC3) was associated with
both hypoacetylation and hypermethylation of histone H3
[9]. However, few studies knew about the mechanisms
underlying the involvement of histone methylation upon
the silencing of RAR beta 2 expression in tumor cells,
until Moisson et al. (2013) confirmed that DNA hyperme-
thylation cannot explain by itself the epigenetic repression
of RAR beta 2 gene [15].
Truly, prostate cancer accelerates the osteoblastic differ-
entiation during the process of metastasis interacting with
bone mophogenetic proteins (BMPs) [16]. Recently, repul-
sive guidance molecule A (RGMA) a GPI-linked mem-
brane protein has been identified as co-receptor of bone
morphogenetic proteins (BMPs) [17]. Kondo et al. (2008)
demonstrated that, RGMA expression was significantly
lower in cancer tissues than in normal ones. However, the
underlying mechanisms are not well understood yet [8].
Also, it is well established that androgen receptor (AR)
plays a critical role in prostate cancer cell proliferation,
survival, and differentiation. But, some reports also dealt
with the potential implication of other two steroid hor-
mone nuclear receptors, estrogen receptor (ER) alpha and
progesterone receptor (PGR) in prostatic carcinogenesis
[18]. In any case, in the normal human prostate, immuno-
histochemical studies have revealed a stromal localization
of ER alpha and PGR, and less or no ER alpha expression
was detected in malignant prostate epithelium in various
prostates [19]. PGR is the major ER alpha responsive gene,
its expression is not detected in malignant prostatic
epithelium [18].
Finally, steroid receptor coactivator 3 (SRC3) is a mem-
ber of the p160 family of coactivators for nuclear hormone
receptors including the androgen receptor. For instance,
previous studies have shown that SRC3 is overexpressed
in prostate cancer cells and its overexpression correlates
with prostate cancer proliferation and is inversely corre-
lated with apoptosis [20].
The aim of this study was to assess the association
between H3K27me3 level and prostate cancer risk and the
correlation of H3K27me3 on EZH2, RAR beta 2, ER alpha,
PGR, and RGMA promoters with clinicopathological vari-
ables including Gleason score, PSA levels and clinical
stages. Therefore, normalizing H3K27me3 by targeting
inhibition of EZH2 seems to become a potential new
method for cancer therapy.
Results
H3K27me3 correlated positively with clinicopathological
parameters
Firstly, using ChIP assay, we demonstrated that H3K
27me3 occupancy at RAR beta 2, ER alpha, PGR, and
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pared to normal tissue unlike to EZH2 promoter. We
did not find obvious H3K27me3 modification signals at
the SRC3 promoter (Figure 1). These results suggest that
EZH2 regulates RAR beta 2, ER alpha, PGR and RGMA.
On the contrary, SRC3 expression would be regulated in
an H3K27me3-independent manner. The H3K27me3
level in tumoral and normal tissues was then explored
by principal component analysis (PCA) to assess the
relationship between Gleason score, PSA levels, and
clinical stages. Additionally, the extracted PCA factors
were used to examine the ability to discriminate between
patients with cancer and healthy patients. PCA showed
that the total variance explained by the first principal
component (Dim1) of PCA was 61.26% whereas the
second principal component (Dim2) of PCA explained
nearly 19.67% of the total variance. As shown in Figure 2,
on the first principal component, a clear discrimination
can be seen between EZH2 gene and RAR beta 2, ER
alpha, PGR and RGMA genes. SRC3 is orthogonal to the
horizontal axis and therefore did not participate to PCAFigure 1 Assessment of H3K27me3 marks in normal and tumoral tissue
marks at six gene loci in prostate cancer tissues. H3K27me3 level on EZH2 wa
tissues (n = 33). Contrariwise, the H3K27me3 level of RAR beta 2, PGR, ER alpha
tissues. The H3K27me3 level on SRC3 in cancer tissue did not reach statistical
input. Analysis of variance, followed by a Tukey multiple comparison test, was
was indicated by letters “a”, “b” and “c”. (N = normal; GS = Gleason score).analysis. PCA results demonstrated a close relationship
between H3K27me3 level and Gleason score, PSA levels
and clinical stages. This means that, patients with a high
proportion of H3K27me3 marks on RAR beta 2, ER
alpha, PGR and RGMA genes have a high Gleason score
and advanced clinical stage.
In a second step, discriminant factorial analysis (DFA)
was applied to the PCA data that take into account the in-
formation contained in the raw data sets. DFA has allowed
classifying patients according to different groups. For that
purpose, patients in the study cohort were divided into
two groups, 75% of patients have formed learning group
and 25% validation group (Table 1). It has been noted that
although Gleason score, PSA levels and clinical stages
variables displayed high correlation, only the Gleason
score was able to distinguish the three groups (N, GS ≤ 7
and GS > 7) with a significant percentage of around 99%.
All patients are correctly classified, only 1 out of 48
patients was misclassified (Table 2). On the validation
group, patients were 100% correctly classified (Table 3).
The graphical representation of patients was described ins using ChIP-qPCR. ChIP analysis indicates the change of H3K27me3
s found to be lower in prostate cancer tissues (n = 32) versus normal
and RGMA was significantly higher in tumoral tissues that in normal
significance compared in normal tissue. The data is expressed as % of
used for statistical analysis. The statistical significant between groups
Figure 2 Principal component analysis (PCA) carried out to explore the relationships between H3K27 levels and clinicopathological
parameters. H3K27me3 level was evaluated by PCA analysis. H3K27me3 levels on ER alpha, RAR beta 2, RGMA and PGR genes correlated
positively with PSA level (PSA), clinical stage (patho) and Gleason score (Gleason).
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GS > 7 groups were observed. The same process was
applied to clinical stages data. Regarding T1 clinical stage
group, correct classification amounting to 80% was ob-
served. Nevertheless, T2 clinical stage group was only 67%
correctly classified. The T3 clinical stage group was not
analyzed because we have only one patient in this group.
None of the three groups (T1, T2 and T3 clinical stage)
was 100% correctly classified, the classification rate was
not satisfactory. However, with PSA levels, it was not
possible to predict the membership of different groups
established relative to H3K27me3 level.
Gene expression in prostate tissues
Two separate epigenetic pathways have been shown to
be dysregulated or impaired in cancer. The first is the
well-known silencing of genes by DNA methylation and
the second is the silencing of genes mediated by the
Polycomb repressor complex 2, which is often independent
of DNA methylation. Thus, to demonstrate the role ofTable 1 Distribution of patients in two groups
Learning group Validation group Total
Normal 25 8 33
Gleason score ≤7 16 3 19
Gleason score > 7 7 5 12
Total 48 16 64
75% of patients allowed establishing learning database and 25%
validation database.H3K27me3 mark on gene silencing, we measured RAR
beta 2, ER alpha, PRG, RGMA, SRC3, AR, and EZH2
mRNA expressions from prostate tissues using RT-qPCR.
Figure 4 depicts the relative mRNA expression and statis-
tical analysis showed significantly higher EZH2, AR and
SRC3 mRNA levels in patients with prostate cancer com-
pared to normal patients. Contrary, RAR beta 2, ER alpha,
PGR, and RGMA mRNA levels were decreased in prostate
cancer tissue compared to normal one. Next, the analysis
of gene expression was made by principal component ana-
lysis (PCA) to find a relationship with clinical pathological
parameters. The first two principal components accounted
for 68.31% of the total variance and explained the contrast
between overexpressed genes (AR, SRC3 and EZH2) and
underexpressed genes (RAR beta 2, ER alpha, PGR and
RGMA). Additional variables (Gleason score, PSA levels
and clinical stages) positively correlated with the overex-
pression of EZH2, SRC3, and AR therefore with the under
expression of RAR beta 2, ER alpha, PRG and RGMA
(Figure 5). Using DFA analysis, only the variable Gleason
score allowed to properly classify and predict patients
belonging to different groups (GS ≤ 7 and GS > 7). On the
other hand, PSA levels and clinical stages did not help es-
tablish the separation into different groups.
To determine whether the gene expression data identi-
fied by mRNAs analysis resulted in biologically meaningful
changes in protein expression, EZH2, RAR beta 2, ER
alpha, PGR, RGMA, SRC3, and AR protein levels were
assessed in prostate tissue samples using western blot
analysis. As shown in Figure 6, the level of EZH2, SRC3
Table 2 Classification of patients with different groups (normal, Gleason score ≤ 7 and Gleason score > 7)
Observed patients Predicted patients Normal Gleason score ≤ 7 Gleason score > 7 % of correct classification
Normal (n = 25) 25 0 0 100
Score ≤7 (n = 16) 0 16 0 100
Score >7 (n = 7) 0 1 6 85.8
Total 25 17 6
This table represents a learning group and represents 75% of patients. The percentage of correctly classified patients corresponds to the ratio of the number of
patients well classified by the total number of patients (n). It is observed that there is one individual of Gleason score >7 group is misclassified. The number in
bold corresponded to patients well classified.
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with a Gleason score of at least 8. On the contrary, RAR
beta 2, ER alpha, PGR, RGMA protein levels were notably
reduced in prostate cancer tissues compared to normal
tissues. These results are consistent with the mRNA
expression levels data.
Effect of DZNep and SAHA on cell viability
To further determinate cell viability, we treated DU145,
PC3 and LNCaP cells with 3-deazaneplanocin A (DZNep)
and suberoylanilide hydroxamic acid (SAHA) using vari-
ous concentrations for 24 h, 48 h and 72 h and then, the
number of viable cells was counted. As shown in Figure 7,
DZNep significantly decreased the cell proliferation in a
concentration-dependent manner. DZNep displayed an
IC50 value of 8.97 μM for DU145 against 10.76 μM for
PC3 and 9.01 μM for LNCaP at 72 h of treatment.
However, SAHA displayed an IC50 value of 2.05 μM for
DU145, 1.88 μM for PC3 and 1.99 for LNCaP at 72 h of
treatment. According to these results, 10 μM DZNep and
2 μM SAHA were chosen for mRNA experiments.
Restoration of mRNA expression by DZNep and SAHA in
prostate cancer cells
To assess the effect of DZNep and SAHA, the levels of
RAR beta 2, ER alpha, PRG, RGMA, SRC3, AR and
EZH2 mRNA were examined in prostate cancer cells
using RT-qPCR. As shown in Figure 8, after 72 h of
treatment, DZNep was able to decrease EZH2 mRNA
expression in LNCaP, PC3 and DU145 cells compared
with control cells treated with DMSO 0.1% (p < 0.05). In
the three cell lines, after 72 h, DZNep induced an increase
of RGMA and RAR beta 2 mRNA levels. This re-
expression was associated with an EZH2 decreased. InTable 3 Classification of patients with different groups (norm
Observed patients Predicted patients Normal Gleaso
Normal (n = 8) 8
Score ≤7 (n = 3) 0
Score >7 (n = 5) 0
Total 8
This table represents a validation group and represents 25% of the patients. The pe
of patients well classified by the total number of patients (n). We observed that allboth AR-negative cell lines, only PC3 cells reactive AR ex-
pression after treatment with DZNep and SAHA. Any ef-
fect of DZNep on SRC3 expression has been observed on
prostate cancer cell lines. However, in LNCaP, DU145 and
PC3 cells there was a moderate increase of SRC3 expres-
sion after 72 h of treatment with SAHA. ER alpha and
PGR expressions in DU145 and PC3 cells were undetected
by RT-qPCR in control cells. However, in these two cell
lines, ER alpha and PGR re-expressions were detected
with DZNep or SAHA treatment (Figure 8).Discussion
The progression of prostate cancer, like other cancers, is
facilitated by the epigenetic silencing of tumor-suppressor
genes [21]. DNA hypermethylation in prostate cancer has
been extensively studied [22,23]. However, histone modifi-
cation patterns have been found to predict the risk of
prostate cancer [24].
The present study clearly pointed out H3K27me3 as an
epigenetic mark involved in the silencing of RAR beta 2,
ER alpha, PGR, and RGMA genes in prostate cancer.
Similarly, one of our previous studies showed that
H3K27me3 marks were also significantly higher in peri-
tumoral tissues from prostate cancer patients compared
to normal tissue. These results suggest that peri-tumoral
tissues seem to present molecular features such as
tumoral tissues and established H3K27me3 like an epigen-
etic mark pathogenically involved in neoplasia trough the
silencing of genes [25]. Previous study has also demon-
strated an increase of RAR beta 2 and Adenomatous
polyposis coli (APC) DNA methylation level in prostate
tissue containing intraepithelial neoplasia and in adjacent
non-neoplastic tissue [26].al, Gleason score ≤ 7 and Gleason score > 7)





rcentage of correctly classified patients corresponds to the ratio of the number
patients are well classified.
Figure 3 Factorial Discriminant Analysis (FAD) carried out to describe the variables that discriminate the three groups of patients.
RAR beta 2, ER alpha, RGMA and PGR variables conflict to EZH2. Variable SRC3 being away from the circle, it wears a low information (left panel).
The graphical representation of patients was used to identify homogeneous groups within the population from the point of view of variable
studied (H3K27me3). Red plots represent normal patients (N), green plots represent patients with Gleason score ≤ 7 (<=7) and blue plots
represent patients with Gleason score >7 (>7) (right panel).
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existing correlation between all the different analyzed var-
iables. Additionally, the DFA analysis was used because
different groups were known and also to help predict
group membership. This enables to include many
variables in the study in order to determine the ones that
discriminated between groups. The results showed an
evident correlation between H3K27me3 level and clinico-
pathological parameters in prostate cancer tissues. How-
ever, it should be clearly noted that, if the overall average
of the variables is significantly different between cancer
and normal tissue, it does not mean that this variable dis-
criminates different assigned classes. Obviously, results
showed that only Gleason score variable is the best pre-
dictor of the clinicopathological parameters which classify
patients into each group according to H3K27me3 level.
The PSA levels and clinical stages allowed separating
normal patients with prostate cancer patients, without
distinguishing different classes of clinical stages and PSA
levels. About the clinical stages, DFA analysis did not
help discriminate T1 and T2 clinical stage groups. More-
over patients with high level of H3K27 marks do not
necessarily have high PSA level.
To examine the correlation between the abundance of
H3K27me3 and gene activity, mRNA transcript levels
were quantified using RT-qPCR. Previous studies have
identified EZH2 as upregulated in prostate cancer [27,28].
Our results exhibited that, the group of patients with
Gleason score >7 showed strong overexpression of EZH2,
AR, and SRC3 and eventually underexpression of RARbeta 2, ER alpha, PRG, and RGMA compared to normal
patients group. The group with Gleason score ≤ 7 is inter-
mediate between the two others. These results are in
agreement with previous studies which showed an
increase of EZH2 in prostate cancer relatively to normal
tissue. Similarly, the results demonstrated that AR was
also increased in prostate cancer tissue. Indeed, AR is a
potent oncogene which plays a crucial role in the early
development of prostate cancer, as well as in metastatic
castration-resistant progression in prostate cancer. Previ-
ous studies also showed that AR expression was tumor
stage-dependent [29]. SCR3 has also been identified as a
key factor in the development of prostate cancer and there
is an upregulation of SRC3 in prostate cancer tissues. In
fact, when AR was activated by hormones, AR bound to
DNA in the nucleus cell and regulated gene expression
through coactivators such as SRC3.
The identification of ER in the prostate gland was an
indicator suggesting that locally produced testosterone
metabolites with estrogenic activity may serve to balance
the androgenic action in this tissue [30]. The data demon-
strated a decrease in ER alpha expression in patients with
Gleason score >7. This result indicated that, the estrogens
via their ER alpha might inhibit growth of prostate cancer
cells. Previously, we demonstrated that patients with
Gleason score at 6 revealed no significant difference in the
expression of ER alpha compared with the normal tissues
[31]. However in this study, a positive correlation was
observed between decreased ER alpha expression and
tumor aggressiveness.
Figure 4 EZH2, AR and SRC3 is upregulated in prostate cancer and inversely correlated with RAR beta 2, ER alpha, PGR and RGMA.
mRNA expression of seven genes were measured using RT-qPCR in normal tissues (n = 38) and cancerous tissues (n = 34). 18S RNA was used as
an internal control in PCR reactions. All genes that have high H3K27me3 levels in their promoter are consistent with the low mRNA expression
levels. In contrast, genes that have low H3K27me3 levels are consistent with high mRNA expression levels. Analysis of variance, followed by a
Tukey multiple comparison test, was used for statistical analysis. The statistical significant between groups was indicated by letters “a”, “b” and “c”.
(N = normal; GS = Gleason score).
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of RGMA in prostate cancer. Li et al. (2012) observed that
RGM proteins played inhibitor role in prostate cancer by
suppressing cell growth, adhesion migration, and invasion
[17]. In a comparative way, our studies showed that
RGMA expression was down-regulated in most of the
prostate cancer tissues and was positively correlated with
Gleason score. On the other hand, another study showed
similar findings in colon cancer [32].
Another key point is the fact that inactivation of tumor
suppressor genes was a major contributing alteration fac-
tor in the initiation or progression of cancer. Like tumor
suppressor genes, RAR beta 2 was recurrently silenced in
prostate cancer, predominantly by epigenetic mechanisms.
Again, previous studies showed that promoter region of
RAR beta 2 was hypermethylated in more than 80% of
human prostate cancer samples and prostate cancer cellsleading to loss of RAR beta 2 expression [15,33]. A clear
relationship was proven between decreased of RAR beta 2
expression and high Gleason score late-stage clinical.
Furthermore, our results showed high proportion of
H3K27me3 marks at RAR beta 2 promoter suggesting a
strong involvement of polycomb group proteins in silen-
cing of RAR beta 2 gene in prostate cancer. Consequently,
RAR beta 2 may be silenced not only by DNA methylation
as previously demonstrated [34].
To provide more evidence that these genes are
H3K27me3-dependent silencing, we assessed the levels
of RAR beta 2, ER alpha, PGR, and RGMA mRNA
using RT-qPCR in PC3, DU145 and LNCaP cell lines
after treatment with 3-Dezaneplanocin-A (DZNep), a
potent pharmacologic inhibitor of EZH2. DZNep is an
S-adenosyl-L-homocysteine hydrolase inhibitor which
works across an indirect mechanism blocking S-
Figure 5 Principal component analysis (PCA) carried out to explore the difference between genes and relationships with clinicopathological
parameters. The analysis of gene expression was made by PCA. On the dimension 1 (Dim 1), a clear discrimination can be noted between
overexpressed genes (AR, SRC3 and EZH2) and under expressed genes (RAR beta 2, ER alpha, PGR and RGMA). The overexpression of AR, SRC3
and EZH2 gene correlated with PSA level (PSA), clinical stage (patho) and Gleason score (Gleason).
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product inhibition. Our results showed that DZNep
induced a re-expression of RAR beta 2 suggesting that
DNA hypermethylation is not a predominant mechan-
ism of silencing of RAR beta 2. It is also well known
that the polycomb complex PRC2 recruits histone dea-
cetylase proteins at the promoter region of target genes
and subsequently mediates epigenetic transcriptional
repression. However, treatment for prostate cancer cells
with SAHA, a potent histone deacetylase (HDAC)
inhibitor, results in depletion of EZH2 and induction of
RAR beta 2 in prostate cancer cell lines. Other genes
such as PGR and ER alpha were also studied because
they have been identified in both normal and prostate
cancer tissues. Few studies have reported the involve-
ment of these two receptors in the prostate cancers
[35]. But currently, neither mutation nor structural
alterations of these receptor genes in prostate cancer
have been reported to be responsible for ER alpha or
PGR down-regulation. Hopefully, further studies in
epigenetics will investigate this issue. However, it was
known from previous studies, that the ER alpha
promoter is extensively methylated both in prostate
cancer cell lines and prostate cancer tissues, leading to
ER alpha gene inactivation in prostate cancer [36].
Other studies have shown no significant difference
between cancer tissues and normal prostate tissues [4].
We also evidenced a significant increase of H3K27me3
marks on ER alpha gene in prostate tumors comparedto normal tissues. Our data added new mechanisms
whereby histone methylation could silence ER alpha gene
in prostate cancer. Besides, an increase of H3K27me3
marks on PGR gene can explain its downregulation in
prostate cancer. These results have been confirmed by
Western blotting in prostate tissues.
Our investigations have also shown an increase of
H3K27me3 on RGMA gene which would explain the
silencing of this gene in prostate cancer. According to the
previous studies, results exhibited that, RGMA mRNA
was decreased in the prostate cancer tissues compared to
normal prostate tissues [10]. However, the mechanisms in-
volved in this regulation of prostate cancer cells are still
unknown. In PC3, DU145 and LNCaP cell lines, we found
reactivation of RGMA expression after DZNep treatment
supporting the hypothesis that RGMA is silenced by
EZH2. In order to compare DZNep to other epigenetics
drugs such as SAHA, we also observed reactivation of
RGMA expression with SAHA. Surely, HDACs bind
PRC2 complex leading to a series of reactions, including
decreasing acetylation of H3K27, favoring its methylation
and inhibiting gene expression. SAHA would be expected
to counteract this activity, resulting in increased acetyl-
ation and gene expression.
It should be noted that H3K27me3 would have no
effect on SRC3 expression. Using ChIP-qPCR, there is
no significant discrepancy between the cancerous group
and the normal group. However, SRC3 was overexpressed
in prostate cancer compared to normal tissues. When we
Figure 6 EZH2 Expression is inversely correlated to RAR beta 2, ER alpha, PGR and RGMA expressions. Protein expressions were analyzed
using antibodies against SRC3 (155 KDa), AR (110 KDa), EZH2 (98 KDa), PGR (80 KDa), ER alphax (66KDa), RAR beta 2 (55 KDa) and RGMA (49 KDa).
Anti-actin antibody (44 KDa) was used as the internal loading control. Representative data of 3 independent experiments is shown (left panel).
Quantification of the western blot data is shown (right panel). The data is normalized to GAPDH (value = means ± SD, all results are statistically
significant, *p < 0.05, **p < 0.001). The data is expressed as relative protein level. (N = Normal; T = Tumor).
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an increase of SRC3 expression which is a histone acetyl-
transferase activity [4].
The AR signalling pathway is a key factor in the devel-
opment and progression of prostate cancer. DZNep
reduces the transcriptional activity of AR in LNCaP cells,
suggesting that DZNep negatively regulated AR expres-
sion. Furthermore, the initiation of prostate cancer has
been linked to activation of AKT pathway due to loss or
mutation of PTEN. Additionally over-expression of AR
and EZH2 appeared to be important to promote the
progression of prostate cancer. The underlying mechan-
ism remained unknown. Previous studies have shown
that, overexpression of AR alone led to a repression of
EZH2 expression while knockdown of AR increased
EZH2 expression in LNCaP cells [37]. This may be due
to activation of AKT promoting EZH2 phosphorylationat Serine 21, which down-regulates its methyltransferase
activity by blocking EZH2 binding to histone H3,
decreasing H3K27me3 marks leading to de-repressing
epigenetic silencing [38].
Moreover, previous studies reported that, SAHA was
more efficient in terms of growth inhibition and induction
of cell death in androgen-responsive cells [39], suggesting
that a component of the activity of SAHA in prostate can-
cer cells relates to the presence of a functional androgen
signalling axis and that HDAC inhibitors decreased AR
protein levels without significantly affecting AR protein
stability [40,41]. Conversely, in DU145 and PC3 cells,
SAHA led to a re-expression of AR. Also, there was no sig-
nificant difference of SAHA activity over EZH2 expression.
This data suggested that for some genes, the silencing
by EZH2 could be an alternative strategy to override to
DNA methylation. Certainly, EZH2 was overexpressed in
Figure 7 Effects of DZNep and SAHA on cell viability. DU145, PC3 and LNCaP cells were treated with DZNep (2–20 μM) and SAHA (0.5-4 μM)
for 24 h, 48 h and 72 h. The percentage of viable cells was determined as the ratio between treated cells and control cells. The results were
expressed as the mean of triplicate independent experiments. IC50 was calculated following formula: EXP(LN(conc > 50%)-((signal > 50%-50)/
(signal > 50%-signal < 50%)XLN(conc > 50%/conc < 50%))).
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of the metastatic process as described in previous studies.
Methods
Biopsy collection
The 137 men were hospitalized at the Clermont-Ferrand
University Medical Center (France) between 2012 and
2013, and had 12 sextant biopsies [42]. With a letter of con-
sent, patients accepted to give a sample for research. This
procedure corresponded to collection of biological samples
declared to "Le Ministère de l’Enseignement Supérieur et
de la Recherche" with registered number: DC-2008-558.
The anatomo-pathological examination diagnosed the stage
of cancer development. Each biopsy was stored in a cryo-
tube containing nitrogen solution at −196°C at the JeanPerrin Center tumorbank, biological resource center (CRB),
accredited under No. AC-2013-1882. The clinicopathologi-
cal characteristics of all the analyzed prostate tissues are
listed in Table 4 and Table 5.
Cell lines and culture conditions
Three human prostate cancer cell lines, including the
DU145, PC3, and LNCaP obtained from american type
culture collection (ATCC, Manassas, VA, USA) were used.
The cells were cultivated in RPMI 1640 medium for
LNCaP, in F-12 K medium for PC3, and in eagle’s mini-
mum essential medium (EMEM) for DU145 (Gibco, Grand
Island, NY, USA). All cultures were supplemented with
10% heat-inactivated fetal bovine serum (FBS) (Life Tech-
nologies, Carlsbad, CA, USA), 1% glutamin, and 100 U/ml
Figure 8 DZNep and SAHA effects on prostate cancer cell lines. Total RNAs were isolated from PC3, DU145 and LNCaP cells treated with 2 μM
SAHA and 10 μM DZNep for 72 h. Results were analyzed by RT-qPCR. Relative changes in gene expressions compared to the control (the value of
control was designed as 1) were calculated using comparative ΔΔCt method. The 18S RNA was used for normalization. Value =means ± SD from at
least three measures, *p < 0.05.
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maintained as monolayers in an incubator within humidi-
fied atmosphere of 95% air and 5% CO2 at 37°C.
Chemical treatments
To determine the optimal concentration of 3-deaza
neplanocin A (DZNep) and suberoylanilide hydroxamic
acid (SAHA) (Sigma-Aldrich St. Louis, MO, USA) in
prostate cancer cell lines, DZNep and SAHA were dis-
solved in dimethyl sulphoxide (DMSO, Sigma-Aldrich,
St Louis, MO, USA). Final DMSO concentration did not
exceeded 0.1%. The same concentration of DMSO was
used as a control for these experiments. We measured cell
viability using a Scepter™ 2.0 Cell Counter (Millipore,
Billerica, MA, USA) in accordance with the manufacturer’s
standard operating procedures. To identify the demethy-
lating and deacetylating effects of DZNep and SAHA,
DU145, LNCaP and PC3 cells were distributed in six-well
culture plates at a density of 0.5×105 cells per well. After
24 hours, cells were treated with increased doses of
DZNep and SAHA using 10 μl DMSO for respectively and
gradually 24, 48 and 72 hours. After treatments, cells were
washed with phosphate buffered saline (PBS, Life Tech-
nologies, Carlsbad, CA, USA), trypsinized, harvested and
the number of viable cells was counted. Viable cells were
presented as a percentage of the untreated cells controland IC50 is done by linear interpolation between concen-
trations just above and beneath 50% inhibition in the
response dose curve.
Chromatin extraction and shearing
Chromatin extraction was carried out on carcinoma and
normal prostate samples (Table 4). Tissues were treated
with 1% formaldehyde for 15 min to crosslink histone to
DNA. The crosslinking reaction was stopped with 0.125 M
fresh glycine for 5 min. After washing by cold PBS, the
samples were grinded with TissueRuptor® (Qiagen, Hilden,
Germany) until getting a homogeneous suspension. The
lysate was centrifuged at 4000 g for 10 min at 4°C and the
cell pellet was re-suspended in lysis buffer (5 mM PIPES
pH 8; 85 mM KCL; 0.5% IGEPAL, protease inhibitor cock-
tail) and incubated in ice for 15 min. Then, nuclei were
centrifuged at 4000 g for 10 min and the pellet was re-
suspended in shearing buffer (Diagenode, Seraing,
Belgium), incubated in ice for 5 min and sonicated
(Bioruptor™ sonicator, Diagenode) for 40 min. This pro-
duced chromatin fragments of 100 to 600 bp suitable for
ChIP assays as they cover 2 to 3 nucleosomes. Immedi-
ately after sonication, the samples were cleaned by centri-
fugation at 4000 g for 10 min at 4°C and supernatants
containing the sheared chromatin were transferred into
new tubes. Sonicated chromatin was used for DNA
Table 5 Summary of clinicopathological parameters in
prostate samples for RT-qPCR
CASES TT NT
Total cases (n = 72) 34 38




















TT: tumoral tissues; NT: normal tissues; PSA: prostate-specific antigen.
Table 4 Summary of clinicopathological parameters in
prostate samples for ChIP-qPCR
CASES TT NT
Total cases (n = 65) 32 33



















TT: tumoral tissues; NT: normal tissues; PSA: prostate-specific antigen.
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shown) or for chromatin immunoprecipitation (ChIP) assay.
Chromatin immunoprecipitation
ChIP was performed using auto ChIP kit (Diagenode)
according to manufacturer’s instructions. Anti-human
H3K27me3 (pAb-069-050, Diagenode) produced in rabbit
and also non-immune rabbit IgG (negative control) (kch-
504-250, Diagenode) were used. The ChIP was carried out
by SX-8X® Automated System (Diagenode) according to
the protocol provided by the manufacturer. The reaction
was incubated for 2 h for antibody coating with protein
A-coated magnetic beads, then for 10 h at 4°C for immu-
noprecipitation reaction. Later on, 1 μL of proteinase K
was added and the reverse cross-linking was performed
for 45 min at 65°C. The immunoprecipitated DNA and
input samples were analyzed by real-time qPCR.
Quantitative real-time PCR
Real-time PCR was performed in triplicate on a 25 μl
reaction containing 1X TaqMan Universal PCR Master
Mix (Applied Biosystems) and 400 nM of each of
forward and reverse primers (Sigma-Aldrich), 250 nM of
probe (Sigma-Aldrich) and 4.25 μL of water. TaqMan
qPCRs were then carried out for EZH2, RAR beta 2, ERalpha, PGR, RGMA, and SRC3 genes. The oligonucleotide
primers and probes are shown in Table 6. The efficiency
of chromatin immunoprecipitation of particular genomic
locus was calculated from qPCR data and reported as a
percentage of starting material: % (ChIP/total input).
% ChIP=total inputð Þ ¼ 2∧ Ct inputð Þ− log %ð Þ= log2ð Þ−Ct ChIPð Þ½ 
 100%
Ct (input) and Ct (ChIP) are threshold values obtained
from exponential phase of qPCR for the immunoprecipated
DNA sample and input sample respectively. log(X%)/log2
accounted for the dilution 1/X of the input.
Reverse transcription and qPCR
One microgram of mRNA from each sample was re-
versely transcribed in a total volume of 15 μl using first
strand cDNA synthesis kit (GE Healthcare Life Science,
Piscataway, NJ, USA) according to the manufacturer’s
instructions. The resulting cDNA was then quantified
with the TaqMan method (ABI Prism 7900 HT, Applied
Biosystems). Duplex PCR was carried out in 96-well plate
using 10 ng of cDNA in a total volume of 25 μl containing
Table 6 Forward, reverse primers and probes used for ChIP-qPCR for amplification of the gene promoter region
Genes qPCR primer sequences qPCR MGB Probes (Taqman®)
EZH2 Forward AGTGCAATGGCGCGATCT TCACCGCAACCTC
Reverse GAGGCATGAGAATCGCTTGAA
RAR beta 2 Forward GCACGTAGGCTGTTGGTCTTT CCAGCCCCGAATC
Reversre GCTGGCTTGTCTGTCATAATTCA
PGR Forward GAGCCGCGTGTCACTAAATTG CGTCGCAGCCGCA
Reverse TCACAAGTCCGGCACTTGAG
ER alpha Forward CCCTGACATTGGCTTAAACATCA TCCAGGCACAACTC
Reverse TCTTTGGGATCGCTCCAAAT
RGMA Forward CTGCCAGGTCGGGAGTGT AGAGGAGCAAGTTTG
Reverse CACAGCCATAGGGCCTTCTC
SRC3 Forward AAAATTAAGGGCAGGGCTAGGA TCCGGATCCCGAGGGAGCTCC
Reverse GTGCGGCCGCTTTCG
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(4369016, Applied Biosystem), 200nM of EZH2, RAR
beta2, ER alpha, PGR, RGMA, SRC3, and AR Applied
Biosystems assays-on-demand: EZH2 (Hs01016789_m1),
RARbeta2 (Hs00977140_m1), ER alpha (Hs00174860_m1),
PGR (Hs01556702_m1), RGMA (Hs00297192_m1), SRC3
(Hs01105251_m1) and AR (Hs00171172_m1), 10 μM 18S
rRNA primers and 5 μM 18S rRNA TaqMan probe. 18S
primers and TaqMan probe were purchased as follows: for-
ward: 5’-CGG CTA CCA CAT CCA AGG AA-3’ , reverse:
5’-GCT GGA ATT ACC GCG GCT-3’ , probe: 5’-TGC
TGG CAC CAG ACT TGC CCT C-3’ (VIC). Data were
collected using an AB Prism 7900 Sequence Detector
System (Applied Biosystem) for 45 cycles (50°C during
2 min, 95°C for 10 min, 95°C for 15 s and 60°C for 1 min).
Samples were normalized to 18S rRNA level. The com-
parative cycle threshold (CT) method (2-ΔΔCt) was used to
calculate the relative gene expression. All data were gener-
ated at least in triplicate and expressed as mean ± SD.
Genes were considered significantly expressed and their
transcript measurable if their corresponding Ct value was
less than or equal to 35.
Western-blotting
Total protein extractions were performed using RIPA
buffer (Sigma-Aldrich) according to the manufacturer’s
instructions. Protein concentration was assayed using
the Bradford method (Bio-Rad, Hercules, CA, USA) and
equal amount of proteins (25 μg) was separated by elec-
trophoresis on 4-12% SDS-PAGE gels (Bio-Rad Laborator-
ies,Hercules, CA, USA) and transferred to polyvinylidene
fluoride membranes (GE healthcare). Membranes were
blocked with 5% nonfat milk in 0.1% TBS- tween for
1 hour at room temperature, washed, and incubated over-
night at 4°C with primary antibodies in 1% nonfat milkand 0.1% TBS-tween. Primary antibodies used were as
follow: anti-EZH2 (1:500, pAb-039-050, Diagenode), anti-
RAR beta 2 (1:500, GTX12011, GeneTex), anti-ER alpha
(1:250, AC-066-100, Diagenode), anti-PGR (1:250, PAB1
2723, Abnova), anti-RGMA (1:250, H00056963-M01,
Abnova), anti-SRC3 (1:750, MAB7999, Abnova, Walnut,
CA, USA), anti-AR (1:1000, GTX73078, GeneTex, Irvine,
CA, USA) and anti-β Actin (1 :4000, CP01, Millipore). A
secondary antibody consisted of anti-mouse IgG or anti-
rabbit IgG alkaline phosphatase conjugates (1:2000, S372B
and S373B respectively, Promega, Madison, WI, USA).
After final washes, blots were developed using Western




All statistical analysis were performed using R 3.0.1 soft-
ware [43] and the statistical packages agricolae [44], HH
[45] and multcomp [46]. All the data obtained were statisti-
cally analyzed with a one-way ANOVA to test the level of
statistical significance of different groups on H3K27me3
levels and relationships between clinicalpathological param-
eters on different genes. Post-hoc procedures were used
when the F-test was significant (p < 0.05). Multiple compar-
isons among means were examined by a Tukey’s Post Hoc
test. The level of statistical significance was set at p < 0.05.
Principal Component Analysis
The major aim of Principal Component Analysis (PCA) is
the orderly simplification of a large number of inter-
correlated measures to a few uncorrelated representative
constructs or factors [47]. In this study, a small number of
linear combinations (called principal components) are de-
rived from a set of variables (genes) measured on several
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the information about the original variables. This goal typ-
ically overrides in empirical research its secondary aim,
which is interpretation of the principal components. To a
large extent, the interpretation of principal components is
generally guided by the degree to which each variable is
associated with a particular component [47]. The main
outputs of the principal component analysis are the vari-
ances of the principal components and two plots: the pro-
jections of the original variables; and the observations
onto the plane made by the two first principal compo-
nents. In the first plot, as all variables are normalized
(mean equal to zero and variance equal to 1), the distances
between the projections of the variables and the centre are
equal to 1, meaning that the projections near the circum-
ference of the circle belong to the plane of the two first
principal components, and the projections near the centre
do not belong to the plane as they appear to be orthog-
onal. Those variables, found to be most closely related to
a component in question are used as a guide for its inter-
pretation. Principal Component Analysis was performed
using the statistical package FactoMineR [48].
Discriminant Analysis
Discriminant analysis is a powerful descriptive and classifi-
catory technique to first describe characteristics that are
specific to distinct groups (called descriptive discriminant
analysis) and secondly classify cases (i.e., patients, subjects,
participants) into pre-existing groups based on similarities
between different cases that belong to a specific group
[49]. Discriminant analysis can answer some questions that
include: (a) in which ways do various groups in a study dif-
fer? (b) What differences exist between and among the
number of groups on a specific set of variables? (c) Which
continuous variables best characterize each group, or, which
continuous variables are not characteristic of the individual
groups? (d) Given the results of a multivariate analysis of
variance indicating that group differences exist in the data,
what specific variables best account for these differences?
[49]. Given two or more groups or populations and a set
of associated variables one often wants to locate a subset
of the variables and associated functions of the subset that
leads to maximum separation among the centroids of the
groups. The goals of a discriminant analysis are about
constructing a set of discriminants that may be used to
describe or characterize group separation based upon a re-
duced set of variables, to analyze the contribution of the
original variables to the separation, and to evaluate the de-
gree of separation. To test the contribution of each vari-
able, Wilks' lambda is used in an ANOVA [48] test of
mean differences in discriminant analysis, so that the
smaller the lambda for an independent variable, the more
that variable contributes to the discriminant function.
Lambda varies from 0 to 1, with 0 representing group meansdiffer and 1 meaning that all group means are the same. The
F test of Wilks' lambda shows which variables contributions
are significant. Discriminant Analysis was performed using
the statistical package rrcov [50].
Conclusion
Based on the overall results, we believe in a direct role of
EZH2 in silencing of RAR beta 2, ER alpha, PGR, and
RGMA genes via H3K27me3 mark in prostate cancer and
therefore indicates adverse prognosis. Treatment with
DZNep led to the reactivation of genes silenced by epigen-
etic mechanisms in prostate cancer. In view of these
results, we demonstrated that histone modifications con-
tributed to the onset and progression of prostate cancer
and H3K27me3 would be considered as a promising bio-
marker. The identification of these molecular markers will
be used to supplement clinical markers and will allow us
to better predict cancer progression.
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